You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtacrynic acid
Accession NumberDB00903  (APRD00251)
TypeSmall Molecule
GroupsApproved
DescriptionA compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. [PubChem]
Structure
Thumb
Synonyms
(2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
acide étacrynique
ácido etacrínico
acidum etacrynicum
Etacrinic acid
Etakrinic acid
Ethacryinic Acid
Ethacrynate
Ethacrynic acid
Methylenebutyrylphenoxyacetic acid
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EdecrinTablet25 mg/1OralKAISER FOUNDATION HOSPITALS2013-01-10Not applicableUs
EdecrinTablet25 mg/1OralAton Pharma, Inc.1967-01-10Not applicableUs
EdecrinTablet25 mgOralValeant Canada Lp Valeant Canada S.E.C.2004-10-15Not applicableCanada
EdecrinTablet25 mg/1OralAvera Mc Kennan Hospital2015-10-02Not applicableUs
Edecrin Tab 50mgTablet50 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1968-12-312004-03-04Canada
Ethacrynic AcidTablet25 mg/1OralOceanside Pharmaceuticals1967-01-10Not applicableUs
Ethacrynic SodiumPowder, for solution50 mg/50mLIntravenousOceanside Pharmaceuticals1967-01-10Not applicableUs
Sodium EdecrinPowder, for solution50 mgIntravenousValeant Canada Lp Valeant Canada S.E.C.1968-12-31Not applicableCanada
Sodium EdecrinPowder, for solution50 mg/50mLIntravenousAton Pharma, Inc.1967-01-10Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethacrynate SodiumInjection, powder, for solution50 mg/50mLIntravenousPar Pharmaceutical, Inc.2015-07-30Not applicableUs
Ethacrynic AcidTablet25 mg/1OralEdenbridge Pharmaceuticals, LLC2016-07-05Not applicableUs
Ethacrynic AcidTablet25 mg/1OralIngenus Pharmaceuticals Nj, Llc2016-07-05Not applicableUs
Ethacrynic SodiumInjection, powder, lyophilized, for solution50 mg/50mLIntravenousMylan Institutional LLC2016-08-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CrinurylAssia
EdecrilMerck
EdecrinaNot Available
EndecrilNot Available
HidromedinNot Available
HydromedinMerck
MingitNot Available
OtacrilNot Available
ReomaxBioindustria
TaladrenMalesci
UregitNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ethacrynate sodium
6500-81-8
Thumb
  • InChI Key: CWCSCNSKBSCYCS-UHFFFAOYSA-M
  • Monoisotopic Mass: 323.9932085
  • Average Mass: 325.12
DBSALT001225
Categories
UNIIM5DP350VZV
CAS number58-54-8
WeightAverage: 303.138
Monoisotopic: 302.011264286
Chemical FormulaC13H12Cl2O4
InChI KeyAVOLMBLBETYQHX-UHFFFAOYSA-N
InChI
InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
IUPAC Name
2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
SMILES
CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
Pharmacology
IndicationFor the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.
Structured Indications
PharmacodynamicsEthacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.
Mechanism of actionEthacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 1Proteinyes
inhibitor
HumanQ13621 details
Sodium/potassium-transporting ATPase subunit alpha-1Proteinyes
inhibitor
HumanP05023 details
Related Articles
AbsorptionOnset of action is rapid, usually within 30 minutes after an oral dose of ethacrynic acid or within 5 minutes after an intravenous injection of ethacrynic acid.
Volume of distributionNot Available
Protein binding> 98%
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOverdosage may lead to excessive diuresis with electrolyte depletion.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ethacrynic Acid Action PathwayDrug actionSMP00097
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Etacrynic acid.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Etacrynic acid.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the diuretic activities of Etacrynic acid.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Etacrynic acid.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etacrynic acid.Withdrawn
AcetovanilloneAcetovanillone may decrease the diuretic activities of Etacrynic acid.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aclarubicin.Investigational
AdapaleneAdapalene may decrease the diuretic activities of Etacrynic acid.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Etacrynic acid.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Etacrynic acid.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Etacrynic acid.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Allopurinol.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Etacrynic acid.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Etacrynic acid.Experimental, Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Etacrynic acid.Approved
AmifostineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Etacrynic acid.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Etacrynic acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amphotericin B.Approved, Investigational
AmrubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amrubicin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Etacrynic acid.Investigational
AnisodamineAnisodamine may decrease the diuretic activities of Etacrynic acid.Investigational
annamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with annamycin.Investigational
AntipyrineAntipyrine may decrease the diuretic activities of Etacrynic acid.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Apraclonidine.Approved
ApramycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Apramycin.Experimental, Vet Approved
ApremilastApremilast may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Arbekacin.Approved
ArbutamineArbutamine may increase the hypokalemic activities of Etacrynic acid.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Etacrynic acid.Approved
Atracurium besylateEtacrynic acid may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the diuretic activities of Etacrynic acid.Withdrawn
AzelastineAzelastine may decrease the diuretic activities of Etacrynic acid.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Etacrynic acid.Investigational
BalsalazideBalsalazide may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Etacrynic acid.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Etacrynic acid.Experimental
BarbitalBarbital may increase the hypotensive activities of Etacrynic acid.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Etacrynic acid.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Etacrynic acid.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Etacrynic acid.Approved
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Etacrynic acid.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Etacrynic acid.Approved
Betulinic AcidBetulinic Acid may decrease the diuretic activities of Etacrynic acid.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Etacrynic acid.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Etacrynic acid.Approved
BortezomibThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etacrynic acid.Approved
BromfenacBromfenac may decrease the diuretic activities of Etacrynic acid.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the diuretic activities of Etacrynic acid.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Etacrynic acid.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Etacrynic acid.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Etacrynic acid.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etacrynic acid.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Etacrynic acid.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Etacrynic acid.Approved
CandoxatrilEtacrynic acid may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Etacrynic acid.Illicit, Vet Approved
CarprofenCarprofen may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Etacrynic acid.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the diuretic activities of Etacrynic acid.Experimental
CelecoxibCelecoxib may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
ChloroquineChloroquine may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etacrynic acid.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Etacrynic acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Etacrynic acid.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cilnidipine.Approved
Cisatracurium besylateEtacrynic acid may decrease the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinEtacrynic acid may increase the nephrotoxic activities of Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Etacrynic acid.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Etacrynic acid.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Etacrynic acid.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid.Approved
ClonixinClonixin may decrease the diuretic activities of Etacrynic acid.Approved
ClozapineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Etacrynic acid.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Etacrynic acid.Approved
CurcuminCurcumin may decrease the diuretic activities of Etacrynic acid.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the diuretic activities of Etacrynic acid.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dapagliflozin.Approved
DaunorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Daunorubicin.Approved
DecamethoniumEtacrynic acid may decrease the neuromuscular blocking activities of Decamethonium.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Etacrynic acid.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Etacrynic acid.Investigational
dersalazinedersalazine may decrease the diuretic activities of Etacrynic acid.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.Approved
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Etacrynic acid.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Etacrynic acid.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Etacrynic acid.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Etacrynic acid.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etacrynic acid.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Etacrynic acid.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etacrynic acid.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Etacrynic acid.Approved
DiclofenacDiclofenac may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Diclofenamide.Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Etacrynic acid.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Etacrynic acid.Approved
DiflunisalDiflunisal may decrease the diuretic activities of Etacrynic acid.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Etacrynic acid.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Etacrynic acid.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etacrynic acid.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etacrynic acid.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etacrynic acid.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dihydrostreptomycin.Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Etacrynic acid.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Etacrynic acid.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Etacrynic acid.Approved
DofetilideEtacrynic acid may increase the QTc-prolonging activities of Dofetilide.Approved
Domoic AcidEtacrynic acid may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideEtacrynic acid may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Etacrynic acid.Investigational
DroxicamDroxicam may decrease the diuretic activities of Etacrynic acid.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Etacrynic acid.Approved
DuloxetineEtacrynic acid may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the diuretic activities of Etacrynic acid.Investigational
E6201E6201 may decrease the diuretic activities of Etacrynic acid.Investigational
EbselenEbselen may decrease the diuretic activities of Etacrynic acid.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Etacrynic acid.Approved, Vet Approved
EnalaprilatEtacrynic acid may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Etacrynic acid.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
EpirizoleEpirizole may decrease the diuretic activities of Etacrynic acid.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Etacrynic acid.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etacrynic acid.Approved
EquileninEquilenin may increase the hypokalemic activities of Etacrynic acid.Experimental
EquilinEquilin may increase the hypokalemic activities of Etacrynic acid.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Etacrynic acid.Approved
EstroneEstrone may increase the hypokalemic activities of Etacrynic acid.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptEtanercept may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Etacrynic acid.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etacrynic acid.Approved, Illicit
EtodolacEtodolac may decrease the diuretic activities of Etacrynic acid.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the diuretic activities of Etacrynic acid.Approved
EtoricoxibEtoricoxib may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Etacrynic acid.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Etacrynic acid.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
exisulindexisulind may decrease the diuretic activities of Etacrynic acid.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the diuretic activities of Etacrynic acid.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the diuretic activities of Etacrynic acid.Approved
FenoterolFenoterol may increase the hypokalemic activities of Etacrynic acid.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etacrynic acid.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Fimasartan.Approved
FloctafenineFloctafenine may decrease the diuretic activities of Etacrynic acid.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Etacrynic acid.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Etacrynic acid.Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FlunixinFlunixin may decrease the diuretic activities of Etacrynic acid.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Etacrynic acid.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Etacrynic acid.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Etacrynic acid.Approved
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Etacrynic acid.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Etacrynic acid.Approved
FormestaneFormestane may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Etacrynic acid.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etacrynic acid.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Etacrynic acid.Approved
FramycetinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Framycetin.Approved
FurosemideFurosemide may increase the ototoxic activities of Etacrynic acid.Approved, Vet Approved
Gallamine TriethiodideEtacrynic acid may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with GENTAMICIN C1A.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Etacrynic acid.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Etacrynic acid.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Etacrynic acid.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Etacrynic acid.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Etacrynic acid.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Etacrynic acid.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Etacrynic acid.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Etacrynic acid.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Etacrynic acid.Approved, Illicit
HexobarbitalHexobarbital may increase the hypotensive activities of Etacrynic acid.Approved
HigenamineHigenamine may decrease the diuretic activities of Etacrynic acid.Investigational
HMPL-004HMPL-004 may decrease the diuretic activities of Etacrynic acid.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etacrynic acid.Approved, Illicit
Hygromycin BThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hygromycin B.Vet Approved
IbuprofenIbuprofen may decrease the diuretic activities of Etacrynic acid.Approved
IbuproxamIbuproxam may decrease the diuretic activities of Etacrynic acid.Withdrawn
IcatibantIcatibant may decrease the diuretic activities of Etacrynic acid.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Idarubicin.Approved
IloprostThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Etacrynic acid.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Etacrynic acid.Approved
IndomethacinIndomethacin may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
IndoprofenIndoprofen may decrease the diuretic activities of Etacrynic acid.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Indoramin.Withdrawn
INNO-206The risk or severity of adverse effects can be increased when Etacrynic acid is combined with INNO-206.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Etacrynic acid.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Etacrynic acid.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Etacrynic acid.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Etacrynic acid.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etacrynic acid.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Etacrynic acid.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isocarboxazid.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Etacrynic acid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Etacrynic acid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Etacrynic acid.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the diuretic activities of Etacrynic acid.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Etacrynic acid.Investigational
IvabradineEtacrynic acid may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Kanamycin.Approved, Vet Approved
KebuzoneKebuzone may decrease the diuretic activities of Etacrynic acid.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etacrynic acid.Approved
KetoprofenKetoprofen may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
KetorolacKetorolac may decrease the diuretic activities of Etacrynic acid.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Etacrynic acid.Approved
LacidipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lacidipine.Approved
LeflunomideLeflunomide may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Levobupivacaine.Approved
LevodopaEtacrynic acid may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etacrynic acid.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etacrynic acid.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Etacrynic acid.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Etacrynic acid.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etacrynic acid.Approved, Investigational
LisofyllineLisofylline may decrease the diuretic activities of Etacrynic acid.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Etacrynic acid.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lofexidine.Approved, Investigational
LornoxicamLornoxicam may decrease the diuretic activities of Etacrynic acid.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.Approved
LoxoprofenLoxoprofen may decrease the diuretic activities of Etacrynic acid.Approved
LumiracoxibLumiracoxib may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Etacrynic acid.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Etacrynic acid.Approved, Investigational
MasoprocolMasoprocol may decrease the diuretic activities of Etacrynic acid.Approved
ME-609ME-609 may increase the hypokalemic activities of Etacrynic acid.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etacrynic acid.Approved
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Etacrynic acid.Approved
Mefenamic acidMefenamic acid may decrease the diuretic activities of Etacrynic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Etacrynic acid.Vet Approved
MeloxicamMeloxicam may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
MesalazineMesalazine may decrease the diuretic activities of Etacrynic acid.Approved
MetamizoleMetamizole may decrease the diuretic activities of Etacrynic acid.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Etacrynic acid.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Etacrynic acid.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid.Approved
MethohexitalMethohexital may increase the hypotensive activities of Etacrynic acid.Approved
MethotrexateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Etacrynic acid.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metipranolol.Approved
MetocurineEtacrynic acid may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideEtacrynic acid may decrease the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Etacrynic acid.Approved, Investigational
MetrizamideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metrizamide.Approved
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Etacrynic acid.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Etacrynic acid.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
MivacuriumEtacrynic acid may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may decrease the diuretic activities of Etacrynic acid.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Etacrynic acid.Approved
MometasoneMometasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etacrynic acid.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Etacrynic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the diuretic activities of Etacrynic acid.Approved
NadololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nadolol.Approved
NafamostatNafamostat may decrease the diuretic activities of Etacrynic acid.Investigational
NaftifineNaftifine may decrease the diuretic activities of Etacrynic acid.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etacrynic acid.Approved
NaproxenNaproxen may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Etacrynic acid.Investigational
NCX 4016NCX 4016 may decrease the diuretic activities of Etacrynic acid.Investigational
NeamineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol.Approved, Investigational
NeomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinEtacrynic acid may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the diuretic activities of Etacrynic acid.Approved
NesiritideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nesiritide.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Netilmicin.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Etacrynic acid.Approved
NicorandilNicorandil may increase the hypotensive activities of Etacrynic acid.Approved
NifedipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Etacrynic acid.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the diuretic activities of Etacrynic acid.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Etacrynic acid.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the diuretic activities of Etacrynic acid.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Etacrynic acid.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Etacrynic acid.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Etacrynic acid.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Obinutuzumab.Approved
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Etacrynic acid.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etacrynic acid.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Etacrynic acid.Approved
OlopatadineOlopatadine may decrease the diuretic activities of Etacrynic acid.Approved
OlsalazineOlsalazine may decrease the diuretic activities of Etacrynic acid.Approved
OmapatrilatEtacrynic acid may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Etacrynic acid.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Etacrynic acid.Approved
OrgoteinOrgotein may decrease the diuretic activities of Etacrynic acid.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain.Approved
OxaprozinOxaprozin may decrease the diuretic activities of Etacrynic acid.Approved
OxprenololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etacrynic acid.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etacrynic acid.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Etacrynic acid.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paclitaxel.Approved, Vet Approved
PancuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Etacrynic acid.Approved
ParecoxibParecoxib may decrease the diuretic activities of Etacrynic acid.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paromomycin.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Etacrynic acid.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etacrynic acid.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Etacrynic acid.Approved, Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Etacrynic acid.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Etacrynic acid.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Phenoxybenzamine.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Etacrynic acid.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etacrynic acid.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pipamperone.Approved
PipecuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pirarubicin.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Etacrynic acid.Approved
PirfenidonePirfenidone may decrease the diuretic activities of Etacrynic acid.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Etacrynic acid.Investigational
PiroxicamPiroxicam may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Plicamycin.Approved, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Etacrynic acid.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Etacrynic acid.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Etacrynic acid.Experimental
PrimidonePrimidone may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Etacrynic acid.Approved
PropacetamolPropacetamol may decrease the diuretic activities of Etacrynic acid.Approved
PropofolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Etacrynic acid.Approved, Investigational
PTC299PTC299 may decrease the diuretic activities of Etacrynic acid.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Puromycin.Experimental
PyrantelEtacrynic acid may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Etacrynic acid.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid.Approved
RapacuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etacrynic acid.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
RescinnamineEtacrynic acid may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etacrynic acid.Approved
ResveratrolResveratrol may decrease the diuretic activities of Etacrynic acid.Experimental, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ribostamycin.Approved
RimexoloneRimexolone may increase the hypokalemic activities of Etacrynic acid.Approved
RiociguatThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Etacrynic acid.Approved
RocuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the diuretic activities of Etacrynic acid.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Etacrynic acid.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
SalicylamideSalicylamide may decrease the diuretic activities of Etacrynic acid.Approved
Salicylic acidSalicylic acid may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Etacrynic acid.Approved
SalsalateSalsalate may decrease the diuretic activities of Etacrynic acid.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Etacrynic acid.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sevoflurane.Approved, Vet Approved
SisomicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sisomicin.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Etacrynic acid.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.Approved
SP1049CThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with SP1049C.Investigational
SpectinomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Spectinomycin.Approved, Vet Approved
SpiraprilEtacrynic acid may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.Approved
SRT501SRT501 may decrease the diuretic activities of Etacrynic acid.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptokinase.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptozocin.Approved
SuccinylcholineEtacrynic acid may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.Approved, Investigational
SulfasalazineSulfasalazine may decrease the diuretic activities of Etacrynic acid.Approved
SulindacSulindac may decrease the diuretic activities of Etacrynic acid.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sulpiride.Approved
SuprofenSuprofen may decrease the diuretic activities of Etacrynic acid.Approved, Withdrawn
TamsulosinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Etacrynic acid.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Telmisartan.Approved, Investigational
TemocaprilEtacrynic acid may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the diuretic activities of Etacrynic acid.Approved
TepoxalinTepoxalin may decrease the diuretic activities of Etacrynic acid.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Etacrynic acid.Approved
TeriflunomideTeriflunomide may decrease the diuretic activities of Etacrynic acid.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Etacrynic acid.Investigational
ThiopentalThiopental may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Etacrynic acid.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Etacrynic acid.Approved
TinoridineTinoridine may decrease the diuretic activities of Etacrynic acid.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Etacrynic acid.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.Approved
TobramycinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tobramycin.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Etacrynic acid.Approved
TolazolineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etacrynic acid.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Etacrynic acid.Approved
TolmetinTolmetin may decrease the diuretic activities of Etacrynic acid.Approved
TopiramateEtacrynic acid may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Etacrynic acid.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid.Approved
TranilastTranilast may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Etacrynic acid.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the diuretic activities of Etacrynic acid.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Etacrynic acid.Withdrawn
TubocurarineEtacrynic acid may decrease the neuromuscular blocking activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the diuretic activities of Etacrynic acid.Investigational, Withdrawn
ValrubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid.Approved, Investigational
VecuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.Approved
VilanterolVilanterol may increase the hypokalemic activities of Etacrynic acid.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etacrynic acid.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Etacrynic acid.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Etacrynic acid.Approved
ZaltoprofenZaltoprofen may decrease the diuretic activities of Etacrynic acid.Approved
ZileutonZileuton may decrease the diuretic activities of Etacrynic acid.Approved, Investigational, Withdrawn
ZomepiracZomepirac may decrease the diuretic activities of Etacrynic acid.Withdrawn
ZorubicinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Zorubicin.Experimental
Food Interactions
  • Take with food to reduce irritation.
References
Synthesis Reference

Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck
& co., Inc.

General ReferencesNot Available
External Links
ATC CodesC03CC01
AHFS Codes
  • 40:28.08
PDB EntriesNot Available
FDA labelDownload (75.2 KB)
MSDSDownload (74 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9591
Blood Brain Barrier-0.6921
Caco-2 permeable+0.5597
P-glycoprotein substrateSubstrate0.54
P-glycoprotein inhibitor INon-inhibitor0.5574
P-glycoprotein inhibitor IINon-inhibitor0.9828
Renal organic cation transporterNon-inhibitor0.9052
CYP450 2C9 substrateNon-substrate0.8508
CYP450 2D6 substrateNon-substrate0.8947
CYP450 3A4 substrateNon-substrate0.5262
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8384
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8344
BiodegradationReady biodegradable0.6545
Rat acute toxicity2.4505 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9228
hERG inhibition (predictor II)Non-inhibitor0.9044
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Aton pharma inc
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg/1
TabletOral25 mg
TabletOral50 mg
Injection, powder, for solutionIntravenous50 mg/50mL
Injection, powder, lyophilized, for solutionIntravenous50 mg/50mL
Powder, for solutionIntravenous50 mg
Powder, for solutionIntravenous50 mg/50mL
Prices
Unit descriptionCostUnit
Sodium edecrin 50 mg vial527.4USD vial
Edecrin sodium 50 mg vial114.0USD vial
Ethacrynic acid 100% powder26.4USD g
Edecrin 25 mg tablet3.19USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point118.5-120.5Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck & co., Inc.
logP3.3Not Available
pKa3.5MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.0194 mg/mLALOGPS
logP3.42ALOGPS
logP3.66ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)2.8ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity72.22 m3·mol-1ChemAxon
Polarizability28.57 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenoxyacetic acid derivatives
Direct ParentPhenoxyacetic acid derivatives
Alternative Parents
Substituents
  • Phenoxyacetate
  • Butyrophenone
  • Phenylpropene
  • Acetophenone
  • Aryl ketone
  • Phenol ether
  • 1,2-dichlorobenzene
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Alkyl aryl ether
  • Alpha-branched alpha,beta-unsaturated-ketone
  • Aryl halide
  • Aryl chloride
  • Vinylogous halide
  • Alpha,beta-unsaturated ketone
  • Enone
  • Acryloyl-group
  • Ketone
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Bowes TJ, Gupta RS: Induction of mitochondrial fusion by cysteine-alkylators ethacrynic acid and N-ethylmaleimide. J Cell Physiol. 2005 Mar;202(3):796-804. [PubMed:15389563 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Ronquist G, Agren GK: A Mg2+- and Ca2+-stimulated adenosine triphosphatase at the outer surface of Ehrlich ascites tumor cells. Cancer Res. 1975 Jun;35(6):1402-6. [PubMed:124205 ]
  2. Proverbio F, Condrescu-Guidi M, Whittembury G: Ouabain-insensitive Na+ stimulation of an Mg-2+ -dependent ATPase in kidney tissue. Biochim Biophys Acta. 1975 Jun 25;394(2):281-92. [PubMed:124600 ]
  3. Valdes RM, Huff MO, El-Masri MA, El-Mallakh RS: Effect of ethacrynic acid on sodium pump alpha isoforms in SH-SY5Y cells. Bipolar Disord. 2003 Apr;5(2):123-8. [PubMed:12680902 ]
  4. Kiil F, Sejersted OM: Analysis of energy metabolism and mechanism of loop diuretics in the thick ascending limb of Henle's loop in dog kidneys. Acta Physiol Scand. 2003 May;178(1):73-82. [PubMed:12713517 ]
  5. Schurek HJ, Aulbert E, Ebel H, Muller-Suur C: Influence of ouabain and ethacrynic acid on sodium transport and NaK-ATPase activity in the isolated perfused rat kidney. Curr Probl Clin Biochem. 1975;4:162-8. [PubMed:127690 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Glutathione transferase activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name:
GSTA2
Uniprot ID:
P09210
Molecular Weight:
25663.675 Da
References
  1. Depeille P, Cuq P, Passagne I, Evrard A, Vian L: Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer. 2005 Jul 25;93(2):216-23. [PubMed:15999103 ]
  2. Awasthi S, Srivastava SK, Ahmad F, Ahmad H, Ansari GA: Interactions of glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate. Biochim Biophys Acta. 1993 Jul 10;1164(2):173-8. [PubMed:8329448 ]
  3. Iersel ML, Ploemen JP, Struik I, van Amersfoort C, Keyzer AE, Schefferlie JG, van Bladeren PJ: Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem Biol Interact. 1996 Oct 21;102(2):117-32. [PubMed:8950226 ]
  4. van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ: Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact. 1997 Dec 12;108(1-2):67-78. [PubMed:9463521 ]
  5. Morrow CS, Smitherman PK, Townsend AJ: Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem Pharmacol. 1998 Oct 15;56(8):1013-21. [PubMed:9776312 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Nanni B, Raffaelli A, Salvadori P: Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties. J Pharm Biomed Anal. 1998 Oct;18(1-2):127-36. [PubMed:9863950 ]
  2. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]
  3. Fehske KJ, Muller WE: High-affinity binding of ethacrynic acid is mediated by the two most important drug binding sites of human serum albumin. Pharmacology. 1986;32(4):208-13. [PubMed:3714803 ]
  4. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. [PubMed:9228014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46